A5000278206- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Head and Neck Surgical Oncology
- Oral health in cancer treatment
- Brain Metastases and Treatment
- Peptidase Inhibition and Analysis
- Colorectal and Anal Carcinomas
- Ear and Head Tumors
- Lymphoma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Salivary Gland Tumors Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Cancer-related molecular mechanisms research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- NF-κB Signaling Pathways
- Boron Compounds in Chemistry
- Esophageal Cancer Research and Treatment
- Effects of Radiation Exposure
- Cervical Cancer and HPV Research
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
The Ohio State University Wexner Medical Center
2018-2025
Atrium Health Wake Forest Baptist
2014-2025
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2019-2025
The Ohio State University
2018-2025
Ohio University
2022
RELX Group (United States)
2020
Wake Forest University
2014-2019
McGill University
2015
Icahn School of Medicine at Mount Sinai
2009-2015
Mount Sinai Hospital
2014
<h3>Importance</h3> Dual blockade of programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) may overcome immune checkpoint inhibition. It is unknown whether dual can potentiate antitumor activity without compromising safety in patients with recurrent or metastatic head neck squamous cell carcinoma (R/M HNSCC) low no PD-L1 tumor expression. <h3>Objective</h3> To assess objective response rate durvalumab combined tremelimumab. <h3>Design, Setting,...
Limited resection has been increasingly used in older patients with stage IA lung cancer. However, the equivalency of limited versus lobectomy according to histology is unknown.We identified than 65 years invasive adenocarcinoma or squamous cell carcinoma ≤ 2 cm who were treated (wedge segmentectomy) Surveillance, Epidemiology, and End Results-Medicare database. We estimated propensity scores that predicted use compared survival lobectomy. Treatments considered equivalent if upper 95th...
PURPOSE Oral mucositis (OM) remains a common, debilitating toxicity of radiation therapy (RT) for head and neck cancer. The goal this phase IIb, multi-institutional, randomized, double-blind trial was to compare the efficacy safety GC4419, superoxide dismutase mimetic, with placebo reduce duration, incidence, severity severe OM (SOM). PATIENTS AND METHODS A total 223 patients (from 44 institutions) locally advanced oral cavity or oropharynx cancer planned be treated definitive postoperative...
Abstract Purpose: A phase II multi-institutional clinical trial was conducted to determine overall survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated a combination of cetuximab nivolumab. Patients Methods: R/M HNSCC were 500 mg/m2 i.v. on day 14 as lead-in followed by nivolumab 240 mg 1 15 each 28-day cycle. Expression p16 programmed death-ligand (PD-L1) archived tumors determined. Tumor-tissue–modified human papillomavirus...
Abstract BACKGROUND Oral mucositis is the dose‐limiting toxicity for patients receiving concurrent chemoradiotherapy regimens tumors of head and neck area. Currently, management established includes use topical anesthetics systemic analgesics. Based on clinical evidence pain alleviation by morphine in with some inflammatory painful conditions, a study was undertaken to determine this effect mucositis‐associated pain. METHODS Twenty‐six malignancies treated concomitant carcinoma who had...
We hypothesized the combination of cetuximab and nivolumab would improve survival in recurrent and/or metastatic (R/M) HNSCC by providing synergy cancer control evaluated toxicities efficacy combination. Effects sequential administration anti-Programmed Cell Death-1 checkpoint inhibitors (CPI) were also explored. Patients who failed at least one line palliative treatment for incurable treated with 500 mg/m2 IV on Day (D)-14 as a lead-in followed 240 D1 D15 every 28-D cycle. Electronic health...
Abstract Purpose: Tumoral programmed cell death ligand-1 (PD-L1) expression is common in human papillomavirus (HPV)–associated head and neck squamous carcinoma (HNSCC). We assessed whether a DNA vaccine targeting HPV-16/18 E6/E7 with IL12 adjuvant (MEDI0457) combined the PD-L1 inhibitor durvalumab could enhance HPV-specific T-cell response improve outcomes recurrent/metastatic HPV-16/18–associated HNSCC. Patients Methods: In this phase Ib/IIa study, immunotherapy-naïve patients ≥1 previous...
To determine the potential clinical utility of peripheral opioid action using a model cancer treatment-induced inflammation and pain that allowed for topical application morphine in damaged tissue (oral mucosa). This pilot study followed two blocks design. Ten patients with painful oral mucositis were enrolled first block (dose-response relationship finding) randomized groups to receive rinses 15 ml either 1 per thousand or 2 solution. Twenty-two into second (efficacy safety determination)....
Rationale: Radiotherapy (RT) is considered the standard treatment for patients with stage I or II non–small lung cancer who are not surgical candidates because of comorbities preferences against surgery.Objectives: To compare outcomes treated RT alone those were untreated to assess effect on survival.Methods: Using Surveillance, Epidemiology and End Results (SEER) registry linked Medicare files, we identified 6,065 unresected histologically confirmed cell cancer, diagnosed between 1992 2002....
Objectives: Cisplatin remains the pivotal chemotherapy in squamous cell carcinoma of head and neck (SCCHN), with nephrotoxicity considered dose-limiting toxicity. The purpose our study was to propose an outpatient high-dose cisplatin protocol aimed at preventing analyze results its utilization patients SCCHN treated concurrent radiotherapy. Materials Methods: We retrospectively evaluated 82 radiotherapy institution. Acute kidney injury (AKI) chronic disease were defined by Kidney Disease...
Dusquetide, a novel Innate Defense Regulator, modulates the innate immune system at key convergence point in intracellular signaling pathways and has demonstrated activity both reducing inflammation increasing clearance of bacterial infection. immunity also been implicated pathogenesis oral mucositis (OM), universal toxicity chemoradiation therapy (CRT). Testing hypothesis that dusquetide can mitigate development duration OM, preclinical studies have completed correlated with interim results...
Background Small cell lung cancer (SCLC) is a common which presents with extensive stage disease at time of diagnosis in two-thirds patients. For treatment advanced disease, traditional platinum doublet chemotherapy induces response rates up to 80% but few durable responses. CPI-613 novel anti-cancer agent that selectively inhibits the altered form mitochondrial energy metabolism tumor cells. Methods We evaluated single-arm, open-label phase II study patients relapsed or refractory SCLC. was...
PurposeNo Food and Drug Administration-approved intervention exists for oral mucositis (OM) from chemoradiotherapy (CRT) used to treat head neck cancers. RRx-001 is a hypoxia-activated, cysteine-directed molecule that affects key pathways involved in OM pathogenesis. This phase 2a, multi-institutional trial was designed assess the safety feasibility of 3 schedules fixed concentration RRx-001; standard-of-care arm included identify potential signals efficacy further study.Methods...
Abstract BACKGROUND: The potential role of postoperative radiation therapy (PORT) for patients who have completely resected, stage III nonsmall cell lung cancer (NSCLC) with N2 disease remains controversial. By using population‐based data, the authors this report compared survival a concurrent cohort elderly had treated and without PORT. METHODS: Surveillance, Epidemiology, End Results (SEER) registry linked to Medicare records, 1307 were identified NSCLC lymph node involvement diagnosed...
Selected patients with brain metastases (BM) are candidates for radiotherapy. A lactatogenic metabolism, common in BM, has been associated radioresistance. We demonstrated that BM express nitric oxide (NO) synthase 2 and administration of its substrate l-arginine decreases tumor lactate patients. In a placebo-controlled trial, we showed before each fraction enhanced the effect radiation, improving control BM. Studies preclinical models radiosensitization is NO-mediated mechanism secondary to...